	US 12,252,551 B2
	Methods and kits for diagnosing and/or treating peripheral neuropathy
Chih-Cheng Chen, Taipei (TW); and Yu-Chia Chuang, Taipei (TW)
Assigned to Academia Sinica, Taipei (TW)
Appl. No. 16/978,278
Filed by Academia Sinica, Taipei (TW)
PCT Filed Mar. 5, 2019, PCT No. PCT/US2019/020638 § 371(c)(1), (2) Date Sep. 4, 2020, PCT Pub. No. WO2019/173258, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/638,338, filed on Mar. 5, 2018.
Prior Publication US 2021/0355207 A1, Nov. 18, 2021
Int. Cl. C07K 16/18 (2006.01); A61K 31/135 (2006.01); A61K 31/195 (2006.01); A61K 31/485 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07K 16/28 (2006.01); C07K 16/44 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/44 (2013.01) [A61K 31/135 (2013.01); A61K 31/195 (2013.01); A61K 31/485 (2013.01); A61K 45/06 (2013.01); A61P 25/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01)]

3 Claims

1. A monoclonal antibody that specifically binds to an epitope of advillin comprising,

a heavy chain variable region comprising a heavy chain complementarity-determining region 1 (HCDR1), a HCDR2, and a HCDR3 having the amino acid sequences of SEQ ID NOs: 22, 24, and 26, respectively; and

a light chain variable region comprising a light chain complementarity-determining region 1 (LCDR1), a LCDR2, and a LCDR3 having the amino acid sequences of SEQ ID NOS: 30, 32, and 34, respectively.